IQVIA Holdings Inc. (NYSE:IQV) Given Average Recommendation of “Moderate Buy” by Analysts

by · The Markets Daily

IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $248.00.

A number of research firms have recently issued reports on IQV. Stifel Nicolaus lifted their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Robert W. Baird raised their price objective on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. raised their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th.

Check Out Our Latest Research Report on IQVIA

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently modified their holdings of the company. National Pension Service grew its holdings in shares of IQVIA by 6.6% during the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock worth $72,646,000 after buying an additional 23,411 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in IQVIA during the second quarter worth approximately $5,046,000. Engineers Gate Manager LP purchased a new stake in IQVIA in the 2nd quarter worth approximately $632,000. SVB Wealth LLC boosted its holdings in shares of IQVIA by 7.4% during the second quarter. SVB Wealth LLC now owns 4,349 shares of the medical research company’s stock worth $840,000 after purchasing an additional 300 shares during the last quarter. Finally, NewEdge Advisors LLC grew its position in shares of IQVIA by 1.2% in the second quarter. NewEdge Advisors LLC now owns 35,788 shares of the medical research company’s stock valued at $6,915,000 after purchasing an additional 420 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE IQV opened at $271.39 on Friday. The stock has a market capitalization of $44.67 billion, a price-to-earnings ratio of 33.67, a PEG ratio of 2.31 and a beta of 1.18. The business’s 50 day moving average is $245.20 and its two-hundred day moving average is $200.94. IQVIA has a 12-month low of $154.50 and a 12-month high of $273.88. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period last year, the firm earned $2.81 EPS. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts expect that IQVIA will post 11.56 EPS for the current year.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

See Also